OKYO Pharma Limited (OKYO)

OKYO Pharma Income Statement

Financials in millions USD. Fiscal year is April - March.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2024	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020
Cost of Revenue	4.49	7.51	6.85	4.61	3.02	1
Gross Profit	-4.49	-7.51	-6.85	-4.61	-3.02	-1
Research & Development	5.86	8.24	6.34	1.61	0.35	0.51
Operating Expenses	5.86	8.24	6.34	1.61	0.35	0.51
Operating Income	-10.35	-15.75	-13.19	-6.22	-3.37	-1.5
Interest Expense	-1.81	-1.05	-0.1	-	-0	-0
Interest & Investment Income	-	-	-	-	-	0.05
EBT Excluding Unusual Items	-12.17	-16.8	-13.28	-6.22	-3.37	-1.46
Other Unusual Items	-	-	-	-	-0.01	-0.13
Pretax Income	-12.17	-16.8	-13.28	-6.22	-3.38	-1.59
Income Tax Expense	-1.48	0.02	-0.01	-0.79	-0.02	-0.07
Earnings From Continuing Operations	-10.69	-16.83	-13.27	-5.43	-3.35	-1.51
Net Income	-10.69	-16.83	-13.27	-5.43	-3.35	-1.51
Net Income to Common	-10.69	-16.83	-13.27	-5.43	-3.35	-1.51
Shares Outstanding (Basic)	33	29	22	15	10	9
Shares Outstanding (Diluted)	33	29	22	15	10	9
Shares Change (YoY)	42.96%	31.84%	47.74%	45.55%	12.98%	15.87%
EPS (Basic)	-0.32	-0.57	-0.60	-0.36	-0.32	-0.17
EPS (Diluted)	-0.32	-0.57	-0.60	-0.36	-0.32	-0.17
Free Cash Flow	-2.94	-9.49	-7.7	-5.47	-1.61	-1.2
Free Cash Flow Per Share	-0.09	-0.32	-0.35	-0.36	-0.15	-0.13
EBITDA	-10.35	-15.75	-13.18	-6.22	-3.36	-1.5
D&A For EBITDA	0	0	0	0	0	0
EBIT	-10.35	-15.75	-13.19	-6.22	-3.37	-1.5

Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q